Literature DB >> 33539406

Carriage rates and antimicrobial sensitivity of pneumococci in the upper respiratory tract of children less than ten years old, in a north Indian rural community.

Sambuddha Kumar1, Debjani Ram Purakayastha2, Arti Kapil1, Siddhartha Saha3, Fatimah S Dawood3, Bimal Kumar Das1, Ritvik Amarchand2, Rakesh Kumar2, Kathryn E Lafond3, Seema Jain3, Anand Krishnan2.   

Abstract

Pneumococcal carriage studies are important for vaccine introduction and treatment strategies. Pneumococcal carriage rates estimated in this cohort study among children in a rural community of northern India. Between August 2012 and August 2014, trained nurses made weekly home visits to screen enrolled children aged <10 years for acute upper or lower respiratory infections (AURI/ALRI) in Ballabgarh, Haryana. Nasal swab from infants aged <1year and throat swab from children aged ≥1 year were collected. All specimens were cultured for pneumococci; isolates were serotyped and subjected to antimicrobial susceptibility testing. During the study period, 4348 nasal/throat swabs collected from children with clinical features of ARI (836 ALRI, 2492 AURI) and from 1020 asymptomatic children. Overall pneumococcal carriage was 5.1%, the highest carriage rate among children <1 year of age (22.6%). The detection rates were higher among children with ARI (5.6%; 95% CI: 4.8-6.4) than asymptomatic children (3.3%; 95% CI: 2.3-4.6). Among 220 pneumococcal isolates, 42 diverse serotypes were identified, with 6B/C (8.6%), 19A (7.2%), 19F (6.8%), 23F (6.4%), 35A/B/C (6.4%), 15B (5%), 14 (4.5%) and 11A/C/D (3.2%) accounting for 50%. Forty-five percent of the serotypes identified are included in the current formulation of 13-valent pneumococcal conjugate vaccine. Ninety-six percent of isolates were resistant to co-trimoxazole, 9% were resistant to erythromycin, and 10% had intermediate resistance to penicillin with minimum inhibitory concentration ranges (0.125 to 1.5 μg/ml). Pneumococcal detection was relatively low among children in our study community but demonstrated a diverse range of serotypes and half of these serotypes would be covered by the current formulation of 13-valent pneumococcal vaccine.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33539406      PMCID: PMC7861412          DOI: 10.1371/journal.pone.0246522

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  29 in total

Review 1.  Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group.

Authors:  Catherine Satzke; Paul Turner; Anni Virolainen-Julkunen; Peter V Adrian; Martin Antonio; Kim M Hare; Ana Maria Henao-Restrepo; Amanda J Leach; Keith P Klugman; Barbara D Porter; Raquel Sá-Leão; J Anthony Scott; Hanna Nohynek; Katherine L O'Brien
Journal:  Vaccine       Date:  2013-12-17       Impact factor: 3.641

2.  Assessing the Impact of Pneumococcal Conjugate Vaccines.

Authors:  David R Murdoch
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

3.  Pneumococcal nasopharyngeal colonization in young South Indian infants.

Authors:  C L Coles; R Kanungo; L Rahmathullah; R D Thulasiraj; J Katz; M Santosham; J M Tielsch
Journal:  Pediatr Infect Dis J       Date:  2001-03       Impact factor: 2.129

4.  High nasopharyngeal carriage of drug resistant Streptococcus pneumoniae and Haemophilus influenzae in North Indian schoolchildren.

Authors:  Amita Jain; Pradeep Kumar; Shally Awasthi
Journal:  Trop Med Int Health       Date:  2005-03       Impact factor: 2.622

Review 5.  The fundamental link between pneumococcal carriage and disease.

Authors:  Birgit Simell; Kari Auranen; Helena Käyhty; David Goldblatt; Ron Dagan; Katherine L O'Brien
Journal:  Expert Rev Vaccines       Date:  2012-07       Impact factor: 5.217

6.  Nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  C Wattal; J K Oberoi; P K Pruthi; Suresh Gupta
Journal:  Indian J Pediatr       Date:  2007-10       Impact factor: 1.967

7.  Surveillance of invasive pneumococcal disease in Colombo, Sri Lanka.

Authors:  R Batuwanthudawe; K Karunarathne; M Dassanayake; S de Silva; M K Lalitha; K Thomas; M Steinhoff; N Abeysinghe
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

8.  Increased Nasopharyngeal Density and Concurrent Carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Are Associated with Pneumonia in Febrile Children.

Authors:  Sopio Chochua; Valérie D'Acremont; Christiane Hanke; David Alfa; Joshua Shak; Mary Kilowoko; Esther Kyungu; Laurent Kaiser; Blaise Genton; Keith P Klugman; Jorge E Vidal
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 9.  Challenges of Empirical Antibiotic Therapy for Community-Acquired Pneumonia in Children.

Authors:  Charlene M C Rodrigues
Journal:  Curr Ther Res Clin Exp       Date:  2017-01-16

10.  Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.

Authors:  Brian Wahl; Katherine L O'Brien; Adena Greenbaum; Anwesha Majumder; Li Liu; Yue Chu; Ivana Lukšić; Harish Nair; David A McAllister; Harry Campbell; Igor Rudan; Robert Black; Maria Deloria Knoll
Journal:  Lancet Glob Health       Date:  2018-07       Impact factor: 26.763

View more
  1 in total

1.  Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).

Authors:  Konstantinos Liatsikos; Angela Hyder-Wright; Sherin Pojar; Tao Chen; Duolao Wang; Kelly Davies; Christopher Myerscough; Jesus Reine; Ryan E Robinson; Britta Urban; Elena Mitsi; Carla Solorzano; Stephen B Gordon; Angela Quinn; Kaijie Pan; Annaliesa S Anderson; Christian Theilacker; Elizabeth Begier; Bradford D Gessner; Andrea Collins; Daniela M Ferreira
Journal:  BMJ Open       Date:  2022-07-07       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.